The Company tests its goodwill and its indefinite-lived intangible assets for impairment annually as of the first day of its fourth fiscal quarter and in interim periods if certain events occur indicating the carrying value may be impaired. There were no indicators of goodwill and in-process research and development (“IPR&D”) impairment noted during the three and six months ended April 3, 2026 and March 28, 2025, respectively.


		As of
	Weighted Average Amortization Period (Years)	April 3, 2026						October 3, 2025
		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Developed technology and other	6.4	$	1,396.5	$	(750.7)	$	645.8	$	1,396.5	$	(678.5)	$	718.0
Technology licenses	3.2	106.7		(33.7)		73.0		167.0		(78.8)		88.2
In-process research and development		2.8		—		2.8		2.8		—		2.8
Total intangible assets		$	1,506.0	$	(784.4)	$	721.6	$	1,566.3	$	(757.3)	$	809.0

Fully amortized intangible assets are eliminated from both the gross and accumulated amortization amounts in the first quarter of each fiscal year. There were no transfers of IPR&D assets to definite-lived intangible assets during the three and six months ended April 3, 2026. During each of the three and six months ended March 28, 2025, $24.7 million of IPR&D assets were transferred to definite-lived intangible assets, and are being amortized over their useful lives of eight years. Amortization expense related to definite-lived intangible assets was $42.9 million and $87.5 million for the three and six months ended April 3, 2026,

respectively, primarily recorded within cost of goods sold. Amortization expense related to definite-lived intangible assets was $45.6 million and $94.0 million for the three and six months ended March 28, 2025, respectively, primarily recorded within cost of goods sold.

Annual amortization expense for the next five fiscal years related to definite-lived intangible assets, excluding IPR&D, is expected to be as follows (in millions):